1. The use of anti-CD20 afukozilirovannogo with the amount of fucose 60% or less for the manufacture of a medicament for treating cancer in combination with an inhibitor mTOR.2. Use according to claim 1, characterized in that the amount of fucose is from 40 to 60% .3. Use according to claim 1, characterized in that the amount of fucose is 50% or menee.4. Use according to claim 1, characterized in that said cancer is a cancer disease where expressed CD20.5. Use according to claim 4, characterized in that said cancer disease, at which expressed CD20, is a B-cell non-Hodgkins lymphoma (NHL) .6. Use according to claim 1, characterized in that said afukozilirovannoe CD20 antibody is an anti-CD20 type II.7. Use according to claim 1, characterized in that said antibody is a humanized antibody B-Ly1.8. Use according to claim 7, characterized in that said mTOR inhibitor is rapamycin, or analog or derivative rapamitsina.9. Use according to claim 7, characterized in that said inhibitor is an mTOR everolimus.10 or temsirolimus. Use according to any one of claims 1-9, characterized in that it is administered one or more additional other cytotoxic, chemotherapeutic or anti-cancer agent or compound, or ionizing radiation, which enhance the effects of such agentov.11. A composition comprising an antibody against CD20 afukozilirovannoe with the amount of fucose 60% or less and an mTOR inhibitor for the treatment raka.12. A composition according to claim 11, characterized in that said afuk1. Применение афукозилированного антитела против CD20 с количеством фукозы 60% или менее для изготовления лекарственного средства для лечения рака в комбинации с ингибитором mTOR.2. Применение по п.1, характеризующееся тем, что количество фукозы составляет от 40 до 60%.3. Применение по п.1, характеризующееся тем, что количество фукозы составляет 50% или менее.4. Применение по п.1, характеризующееся тем, что указанное раковое заболевание представляет собой раковое заболевание, при котором экспрессиру
